Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

5 December 2014
veeva-big

In one of the opening sessions of the Veeva Commerical Summit 2014, cloud-based life sciences provider Veeva's co-founder and president Matt Wallach asserted that “transparency” will force you to understand your cause better, and that will be good for the industry.”

Transparency was the hot topic in a round-table on disclosure between pharma legal experts, a compliance specialist and pharma IT specialist.

A TRANSFER OF VALUE

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical